SPC324
avelumab
Status:
VeittApplication date:
21.12.2020Application published:
15.1.2021Grant published:
15.11.2022
Max expiry date:
19.9.2032Medicine name:
Bavencio - avelumabMedicine for children:
No
Timeline
Today
21.12.2020Application
15.1.2021Publication
15.11.2022Registration
19.9.2032Expires
Marketing license
IS authorization number:
EU/1/17/1214/001Date:
10.8.2020
Foreign authorization number:
EU1/17/1214Date:
18.9.2017
Owner
Name:
Merck Patent GmbHAddress:
Frankfurter Strasse 250, Darmstadt DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2785375